FindTrial
Sign In

PSMA Positron emission tomography (PET) scan

DIAGNOSTIC_TEST2 trials

Sponsors

Université de Sherbrooke, University of California, San Francisco

Conditions

Castration-Resistant Prostate CarcinomaMetastatic Castration-resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneStage IVB Prostate Cancer AJCC v8

Phase 2

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Active, not recruitingNCT05924672
University of California, San FranciscoCastration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IVB Prostate Cancer AJCC v8
Start: 2024-08-30End: 2027-03-31Updated: 2026-01-14

Unknown Phase

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
CompletedNCT04000776
Université de SherbrookeMetastatic Castration-resistant Prostate Cancer
Start: 2019-12-16End: 2023-06-30Updated: 2023-08-28

Related Papers

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
Cancer Imaging2025-07-15
Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2024-01-295 citations
Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.
Journal of Clinical Oncology2023-06-011 citations